Laas, E.; Bresset, A.; Féron, J.-G.; Le Gal, C.; Darrigues, L.; Coussy, F.; Grandal, B.; Laot, L.; Pierga, J.-Y.; Reyal, F.;
et al. HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens. Cancers 2021, 13, 370.
https://doi.org/10.3390/cancers13030370
AMA Style
Laas E, Bresset A, Féron J-G, Le Gal C, Darrigues L, Coussy F, Grandal B, Laot L, Pierga J-Y, Reyal F,
et al. HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens. Cancers. 2021; 13(3):370.
https://doi.org/10.3390/cancers13030370
Chicago/Turabian Style
Laas, Enora, Arnaud Bresset, Jean-Guillaume Féron, Claire Le Gal, Lauren Darrigues, Florence Coussy, Beatriz Grandal, Lucie Laot, Jean-Yves Pierga, Fabien Reyal,
and et al. 2021. "HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens" Cancers 13, no. 3: 370.
https://doi.org/10.3390/cancers13030370
APA Style
Laas, E., Bresset, A., Féron, J.-G., Le Gal, C., Darrigues, L., Coussy, F., Grandal, B., Laot, L., Pierga, J.-Y., Reyal, F., & Hamy, A.-S.
(2021). HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens. Cancers, 13(3), 370.
https://doi.org/10.3390/cancers13030370
